Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial

Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016

(2017) Theo Vos et al.   LANCET

The role of calcitonin gene–related peptide in peripheral and central pain mechanisms including migraine

(2017) Smriti Iyengar et al.   PAIN

Pathophysiology of Migraine: A Disorder of Sensory Processing

(2017) Peter J. Goadsby et al.   PHYSIOLOGICAL REVIEWS

Episodic and Chronic Migraine Headache: Breaking Down Barriers to Optimal Treatment and Prevention

(2015) Richard B. Lipton et al.   HEADACHE

Migraine: Multiple Processes, Complex Pathophysiology

(2015) R. Burstein et al.   JOURNAL OF NEUROSCIENCE

Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study

(2014) David W Dodick et al.   LANCET NEUROLOGY

Migraine: The seventh disabler

(2013) TJ Steiner et al.   CEPHALALGIA

Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults: Table 1

(2012) S.D. Silberstein et al.   NEUROLOGY

Superchain procedures in clinical trials with multiple objectives

(2012) George Kordzakhia et al.   STATISTICS IN MEDICINE

Adherence with Migraine Prophylaxis in Clinical Practice

(2012) Ariel Berger et al.   Pain Practice

Tolerance and Loss of Beneficial Effect During Migraine Prophylaxis: Clinical Considerations

(2011) Elizabeth W. Loder et al.   HEADACHE

Current practice and future directions in the prevention and acute management of migraine

(2010) Peter J Goadsby et al.   LANCET NEUROLOGY